- Home
- ROIV vs CIEN Comparison
ROIV vs CIEN Comparison
Compare ROIV & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CIEN
- Stock Information
- Founded
- ROIV 2014
- CIEN 1992
- Country
- ROIV United Kingdom
- CIEN United States
- Employees
- ROIV N/A
- CIEN N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CIEN Telecommunications Equipment
- Sector
- ROIV Health Care
- CIEN Utilities
- Exchange
- ROIV Nasdaq
- CIEN Nasdaq
- Market Cap
- ROIV 8.6B
- CIEN 12.8B
- IPO Year
- ROIV N/A
- CIEN 1997
- Fundamental
- Price
- ROIV $15.28
- CIEN $136.49
- Analyst Decision
- ROIV Strong Buy
- CIEN Buy
- Analyst Count
- ROIV 4
- CIEN 15
- Target Price
- ROIV $15.50
- CIEN $115.39
- AVG Volume (30 Days)
- ROIV 7.8M
- CIEN 3.1M
- Earning Date
- ROIV 11-11-2025
- CIEN 09-04-2025
- Dividend Yield
- ROIV N/A
- CIEN N/A
- EPS Growth
- ROIV N/A
- CIEN 3.32
- EPS
- ROIV N/A
- CIEN 0.98
- Revenue
- ROIV $23,233,000.00
- CIEN $4,541,635,000.00
- Revenue This Year
- ROIV N/A
- CIEN $19.58
- Revenue Next Year
- ROIV $281.14
- CIEN $16.23
- P/E Ratio
- ROIV N/A
- CIEN $139.62
- Revenue Growth
- ROIV N/A
- CIEN 12.97
- 52 Week Low
- ROIV $8.73
- CIEN $49.21
- 52 Week High
- ROIV $16.05
- CIEN $139.55
- Technical
- Relative Strength Index (RSI)
- ROIV 82.00
- CIEN 82.72
- Support Level
- ROIV $13.81
- CIEN $90.00
- Resistance Level
- ROIV $14.48
- CIEN $138.35
- Average True Range (ATR)
- ROIV 0.47
- CIEN 5.00
- MACD
- ROIV 0.22
- CIEN 2.96
- Stochastic Oscillator
- ROIV 81.67
- CIEN 95.45
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.